Multi-phase contraceptive preparation based on a natural estrogen

Abstract

The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.

1 . Multiphase product for contraception based on a natural oestrogen with a synthetic progestogen characterized in that the first phase consists of 2 daily dose units of 3 mg of the natural oestrogen oestradiol valerate,
 a second phase consists of 2 groups of daily dose units, where the first group is formed by 5 daily dose units of a combination of 2 mg of oestradiol valerate and at least twice or three times the ovulation-inhibitory dose of a synthetic progestogen,   and the second group is formed by 17 daily dose units of a combination of 2 mg of oestradiol valerate and at least three times or four times the ovulation-inhibitory dose of a synthetic progestogen,   a third phase consists of 2 daily dose units with 1 mg of oestradiol valerate,   and a further phase consists of 2 daily dose units of pharmaceutically acceptable placebo.   
     
     
         2 . Multiphase product according to  claim 1 , characterized in that the synthetic progestational active ingredient is dienogest, drospirenone or a progestogen at at least twice its known ovulation-inhibitory dose.